JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okita, G. T.
Right arrow Articles by Geiling, E. M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okita, G. T.
Right arrow Articles by Geiling, E. M. K.
Journal of Pharmacology And Experimental Therapeutics, Vol. 115, Issue 4, 371-379, 1955
Copyright © 1955 by American Society for Pharmacology and Experimental Therapeutics


METABOLIC FATE OF RADIOACTIVE DIGITOXIN IN HUMAN SUBJECTS

George T. Okita 1, Peter J. Talso 2, John H. Curry Jr. 2, Frederick D. Smith Jr. 2, and E. M. K. Geiling 2

1 Department of Pharmacology, the Department of Medicine and the Argonne Cancer Research Hospital, The University of Chicago and the Department of Medicine, The Stritch School of Medicine, Loyola University, Chicago
2 Department of Pharmacology, the Department of Medicine and the Argonne Cancer Research Hospital, The University of Chicago and the Department of Medicine, The Stritch School of Medicine, Loyola University, Chicago

Biosynthetically labeled C14-digitoxin was administered intravenously in multiple doses to three terminal patients. The various tissue samples obtained at autopsy were assayed for both the unchanged drug and its metabolic products.

The myocardium does not have any special affinity for the cardiac glycoside in comparison to other organs.

On a tissue-weight basis the kidney and the contents of the gall bladder, jejunum, ileum, and colon have the highest concentration of unchanged digitoxin. The gall bladder contents, jejunum contents, and spleen have the highest concentration of metabolic products.

On a whole organ basis the liver has the largest amount of both digitoxin and its metabolic products.

The majority of the administered glycoside is metabolized in the body with the liver being the major organ involved in the detoxification of the drug.

The kidney is the major organ involved in the ultimate removal of digitoxin and its metabolic products.

The probable pathway for the metabolic fate and excretion of C14-digitoxin in terminal patients has been discussed.

Submitted on June 9, 1955







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1955 by the American Society for Pharmacology and Experimental Therapeutics.